Abstract :
Erectile dysfunction (ED) is a disability to achieve or sustain an erection to do satisfying intercourse, that occur at least for three months. Erectile dysfunction patients are significantly increasing every year, especially in male age 40-70 years old. Tadalafil inhibit phosphodiesterase type 5 (PDE5) enzyme 10,000 times more potent than PDE1, PDE2, PDE4 and PDE7; 700 times more potent than PDE6; 900 times more potent than PDE8, PDE9, PDE10, and also 14 times more potent than PDE11A1. In elderly, erectile dysfunction commonly is caused by aging process. In other hand, the condition in young adult is usually caused by physiologic factor or stress. Some studies reported that there is no significant difference between the tadalafil’s pharmacokinetic in young adult and elderly, also in patient with or without diabetes mellitus (DM). The dose of tadalafil does not need to be regulated in patients who have liver function disturbance, DM, elderly, renal function disturbance, patients who take medicine like erythromycin, ketoconazole, itraconazole, protease inhibitor, and medicine that inhibit the CYP3A4 system. Several clinical studies reported that tadalafil can increase erection significantly and the patient able to do sex intercourse successfully. Tadalafil does not affect the blood pressure; heart rate; concentration, motility, and morphology of the sperm; and also does not cause eye disturbance. There was no evidence of teratogenicity, embryotoxicity and foetotoxicity in rats that were given tadalafil 1000 mg/kg/day.
